Latest Conference Articles

A new study from the University of Western Australia has revealed that undergoing cataract surgery on both eyes resulted in a 48% improvement in safety during a driving simulator with patients.

A 2-year study in 80 children found that combination therapy of orthokeratology and atropine 0.01% was 38% more effective than monotherapy for slowing myopia in children with lower myopia.

Louis Pasquale, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, discusses how technology and artificial intelligence has impacted ophthalmology.

Intravitreal aflibercept injection showed a high level of ≥2-step improvement in DRSS compared with sham for patients with moderately severe to severe nonproliferative diabetic retinopathy.

Treatment with subretinal transplantation of allogeneic human retinal progenitor cells showed promising early signs of efficacy as a treatment for individuals with retinitis pigmentosa.

Results of the LEAVO trial presented at AAO 2019 reveal a low level of confidence among investigators for recommending bevacizumab treatment as equivalent to ranibizumab and aflibercept at 100 weeks.

AAV2/5-OPTIRPE65 showed improvements in vision-guided mobility, retinal sensitivity, and foveal-driven visual function for patients with RPE65-associated retinal dystrophy.

A phase 2 trial found that use of risuteganib resulted in 48% of patients with nonexudative age-related macular degeneration gaining 8 or more letters of BCVA.

A new study presented at AAO 2019 found the only FDA-approved pill for interstitial cystitis caused retinal damage in about 25% of patients who had been receiving the treatment.

Data from 2 phase 3 trials, which included more than 1800 patients, examining the efficacy and safety profile of abicipar for the treatment of neovascular age-related macular degeneration were presented at AAO 2019.

Data from a phase 1/2a study show RGX-314, a gene therapy from RegenX, was well tolerated and improved visual acuity in patients.

Results of the phase 1 OPTIC trial reveal ADVM-022 was effective at maintaining visual acuity in patients with wet AMD with a favorable safety profile.

New findings show nearly 2000 children in the US were hospitalized due to a gun-related ocular injury from 2008-2014. Most patients faced uncertain visual status going forward.

A study presented at CCR West found that tocilizumab displayed better biologic persistence compared with other biologics in patients with rheumatoid arthritis who previously received 1 or more other biologics.

A post hoc analysis of the OPAL Beyond and OPAL Broaden studies found tofacitinib improved skin-related symptoms and health-related quality of life in psoriatic arthritis patients with an inadequate response to csDMARDs or TNFi treatment.

A post hoc analysis presented at CCR West found sarilumab outperformed adalimumab and placebo in HbA1c improvement in rheumatoid arthritis patients with diabetes.

A study examining a gene expression classifier from Scipher Medicine called PrismRA found the system could be used to identify at least half of the non-responders with at least 90% accuracy.

A 12-week phase 2 study comparing filgotinib to placebo found the oral, selective JAK1-inhibitor could be an effective treatment for ankylosing spondylitis.

Theresa Lawrence Ford, MD, CEO and medical director of North Georgia Rheumatology Group and board member of the Association of Women in Rheumatology, gives her opinion on the current state of burnout among rheumatologists.

Gail Rodich, MD, discusses what the approval of rituximab, which has approvals for 9 other conditions including rheumatoid arthritis, means for pediatric patients with GPA and MPA.

A new study from CCR West compared the JAK inhibitor therapy to competitors across a clinical trial program involving 5 pivotal phase 3 studies.

Maria Greenwald, MD, rheumatologist, discusses what she sees as a glaring issue in medicine—the lack of knowledge among many physicians as to how much treatments will cost and how to mitigate the impact of those costs.

A study from CCR West 2019 has found that tofacitinib can cut the time to clinically significant pain improvement in psoriatic arthritis patients by nearly half the time when compared to placebo therapy.

Maria Greenwald, MD, rheumatologist with Desert Medical Advances, discusses the results of a study she conducted that sought to identify the most effective ways a physician can advise a patient on how to save money on treatments.

Investigators at CCR West find that kidney transplant patients commonly suffer from gout, even before the transplant.

While conferences and annual meetings are often the place clinicians are exposed to new data, there are often niche areas where they seek further guidance or information. Janet Pope, MD, discusses where she would like to see more research dedicated.

Discussing the importance of implementing a multidisciplinary team when treating conditions that put patients at a predisposition for comorbidities with Rania Al Asmar, MBBS, of Marshall University.

Janet Pope, MD, professor of medicine at the University of Toronto, discusses whether she believes clinicians will ever transition away from DMARDs and biologics due to the high cost and what the alternatives are for those patients.

Elena Myasoedova, MD, of the Mayo Clinic, discusses the results of a study examining the incidence rates of cardiovascular disease in patients with rheumatoid arthritis across 3 decades.

Rania Al Asmar, MBBS, discusses a study she led and authored that examined prevalence and characteristics of patients with rheumatoid arthritis who later developed coronary artery disease.